Search Results - "Dimitriou, F."

Novel adjuvant options for cutaneous melanoma by Dimitriou, F., Long, G.V., Menzies, A.M.

“…Patients with resected stage III and IV melanoma have a high risk of recurrence. As the outcomes for patients with metastatic disease have improved…”
Get full text

FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma by Dimitriou, F., Lo, S.N., Tan, A.C., Emmett, L., Kapoor, R., Carlino, M.S., Long, G.V., Menzies, A.M.

“…We have previously shown that 75% of patients treated with programmed cell death protein 1 (PD-1) with or without CTLA4 who have not progressed by 1 year have…”
Get full text

Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect by Boegeholz, J, Brueggen, C S, Pauli, C, Dimitriou, F, Haralambieva, E, Dummer, R, Manz, M G, Widmer, C C

“…Cancer immunotherapy via immune-checkpoint inhibition (ICI) by antibodies against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and cell death protein 1…”
Get full text

Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study by Dimitriou, F., Namikawa, K., Reijers, I.L.M., Buchbinder, E.I., Soon, J.A., Zaremba, A., Teterycz, P., Mooradian, M.J., Armstrong, E., Nakamura, Y., Vitale, M.G., Tran, L.E., Bai, X., Allayous, C., Provent-Roy, S., Indini, A., Bhave, P., Farid, M., Kähler, K.C., Mehmi, I., Atkinson, V., Klein, O., Stonesifer, C.J., Zaman, F., Haydon, A., Carvajal, R.D., Hamid, O., Dummer, R., Hauschild, A., Carlino, M.S., Mandala, M., Robert, C., Lebbe, C., Guo, J., Johnson, D.B., Ascierto, P.A., Shoushtari, A.N., Sullivan, R.J., Cybulska-Stopa, B., Rutkowski, P., Zimmer, L., Sandhu, S., Blank, C.U., Lo, S.N., Menzies, A.M., Long, G.V.

“…BACKGROUNDMucosal melanoma (MM) is a rare melanoma subtype with distinct biology and poor prognosis. Data on the efficacy of immune checkpoint inhibitors…”
Get full text

Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity by Papadavid, E., Kapniari, E., Pappa, V., Nikolaou, V., Iliakis, T., Dalamaga, M., Jonak, C., Porkert, S., Engelina, S., Quaglino, P., Ortiz‐Romero, P.L., Vico, C., Cozzio, A., Dimitriou, F., Guiron, R., Guenova, E., Hodak, E., Bagot, M., Scarisbrick, J.

“…Summary Background Brentuximab vedotin (BV) was approved as a therapy for mycosis fungoides (MF) based on the ALCANZA trial. Little real‐world data, however,…”
Get full text

Health‐related quality of life in survivors of advanced melanoma treated with anti‐PD1‐based immune checkpoint inhibitors by Looman, E. L., Cheng, P. F., Lai‐Kwon, J., Morgan, L., Wakkee, M., Dummer, R., Dimitriou, F.

“…Background Immune checkpoint inhibitors (ICIs) have significantly improved survival in advanced melanoma but are associated with immune‐related adverse events…”
Get full text

Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre study by Brüggen, M.‐C., Valencak, J., Stranzenbach, R., Li, N., Stadler, R., Jonak, C., Bauer, W., Porkert, S., Blaschke, A., Meiss, F., Nicolay, J. P., Wehkamp, U., Schlaak, M., Nguyen, V.A., Romani, N., Cozzio, A., Gayathri, N., Dimitriou, F., French, L. E., Dummer, R., Guenova, E.

“…Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive type of haematologic precursor malignancy primarily often manifesting in…”
Get full text

Histiocytosis in the dermatological context of the new classification by Lang, C, Maul, J-T, Krähenbühl, L, Dimitriou, F, Dummer, R

“…Histiocytoses comprises a heterogeneous group of inflammatory diseases for which dendritic cells and macrophages are the main cellular components. The…”
Get full text

1607 Multiomic analysis of immune-related adverse events (irAEs) in melanoma patients treated with anti-PD1-based immune checkpoint inhibitors (ICIs) by Dimitriou, F., Cheng, P., Saltari, A., Staeger, R., Tastanova, A., Levesque, M., Long, G., Becher, B., Dummer, R.

Get full text

1054P FDG-PET to predict long-term outcome from anti-PD1 (PD1) therapy in metastatic melanoma by Dimitriou, F., Lo, S., Tan, A.C., Emmett, L., Kapoor, R., Carlino, M., Long, G.V., Menzies, A.M.

Get full text

460 Enhancement of antibody-dependent cellular cytotoxicity is associated with treatment response to extracorporeal photopheresis in Sézary syndrome by Iselin, C., Chang, Y., Schlaepfer, T., Fassnacht, C., Dimitriou, F., Nägeli, M., Pascolo, S., Hoetzenecker, W., Bobrowicz, M., Guenova, E.

Get full text

268 Enhancement of antibody-dependent cellular cytotoxicity is associated with treatment response to extracorporeal photopheresis in Sézary syndrome by Iselin, C., Chang, Y., Fassnacht, C., Bobrowicz, M., Dimitriou, F., Nägeli, M., Schlaepfer, T., Pascolo, S., Hoetzenecker, W., Guenova, E.

Get full text

095 - Long-term disease control after stem cell transplantation in primary cutaneous T-cell lymphoma; a single-center analysis by Dimitriou, F., Nair, G., Schanz, U., French, L.E., Dummer, R., Cozzio, A., Guenova, E.

Get full text

Long-term disease control after stem cell transplantation in primary cutaneous T-cell lymphoma; a single-center analysis by Dimitriou, F., Nair, G., Schanz, U., French, L.E., Dummer, R., Cozzio, A., Guenova, E.

Get full text

809P Outcomes of patients with resected stage III/IV acral or mucosal melanoma treated with adjuvant anti-PD-1 therapy by Jacques, S.K., McKeown, J., Grover, P., Park, B., Zaremba, A., Dimitriou, F., Harunal Rashid, M.F., Namikawa, K., Mooradian, M., Placzke, J., Allayous, C., Mehmi, I., DePalo, D., Wicky, A., Schwarze, J.K., Nakamura, Y., Benannoune, N., Menzies, A.M., Lo, S.N., Carlino, M.S.

Get full text

832P Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A202:01 patients (pts) with metastatic uveal melanoma (mUM) by Dimitriou, F., Hassel, J.C., Orloff, M., Hughes, I., Kapiteijn, E., Mehmi, I., Montazeri, K., Johnson, D.B., Grover, P., Gerard, C.L., Simeone, E., Gaudy Marqueste, C., Cheng, P., Long, G.V., Carvajal, R.D., Dummer, R.

Get full text

1049P Clinical models to predict response in mucosal melanoma (MM) patients (pts) treated with anti-PD-1 (PD1) or combined with ipilimumab (PD1+IPI) by Dimitriou, F., Namikawa, K., Teterycz, P., Reijers, I.L.M., Buchbinder, E., Soon, J., Zimmer, L., Mooradian, M., Vitale, M.G., Armstrong, E., Johnson, D., Guo, J., Lebbe, C., Robert, C., Mandala, M., Bhave, P., Farid, M., Kähler, K.C., Lo, S., Long, G.V.

Get full text

1042P Anti-PD1 (PD1) monotherapy or in combination with ipilimumab (IPI) after BRAF/MEK inhibitors (BRAF/MEKi) in BRAF mutant metastatic melanoma (MM) patients (pts) by Pires da Silva, I., Zakria, D., Ahmed, T., Trojaniello, C., Dimitriou, F., Allayous, C., Gerard, C., Zimmer, L., Lo, S., Michielin, O.A., Lebbe, C., Mangana, J., Ascierto, P.A., Johnson, D., Carlino, M., Menzies, A.M., Long, G.V.

Get full text

Hair Depigmentation and Hair Loss in Advanced Melanoma Treated with Combined Immunotherapy and Targeted Therapy by Dimitriou, Florentia, Mangana, Joanna, Dummer, Reinhard

“…Abstract is missing (Short communication)…”
Get full text

The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases – A multicenter cohort study by Holmberg, Carl-Jacob, Ny, Lars, Hieken, Tina J., Block, Matthew S., Carr, Michael J., Sondak, Vernon K., Örtenwall, Christoffer, Katsarelias, Dimitrios, Dimitriou, Florentia, Menzies, Alexander M., Saw, Robyn PM, Rogiers, Aljosja, Straker, Richard J., Karakousis, Giorgos, Applewaite, Rona, Pallan, Lalit, Han, Dale, Vetto, John T., Gyorki, David E., Tie, Emilia Nan, Vitale, Maria Grazia, Ascierto, Paulo A., Dummer, Reinhard, Cohen, Jade, Hui, Jane YC, Schachter, Jacob, Asher, Nethanel, Helgadottir, H., Chai, Harvey, Kroon, Hidde, Coventry, Brendon, Rothermel, Luke D., Sun, James, Carlino, Matteo S., Duncan, Zoey, Broman, Kristy, Weber, Jeffrey, Lee, Ann Y., Berman, Russell S., Teras, Jüri, Ollila, David W., Long, Georgina V., Zager, Jonathan S., van Akkooi, Alexander, Olofsson Bagge, Roger

“…Guidelines addressing melanoma in-transit metastasis (ITM) recommend immune checkpoint inhibitors (ICI) as a first-line treatment option, despite the fact that…”
Get full text